HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4791
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Gene Labs Inc
871 Industrial Road, Building J, San Carlos, CA, 94070
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
GREGORY R REYES
PRINCIPAL INVESTIGATOR
(415) 594-1600
Business Contact:
() -
Research Institution:
n/a
Abstract
HTLV-III/LAV IS A RECENTLY DESCRIBED HUMAN RETROVIRUS LINKEDBOTH MOLECULAR- AND SEROEPIDEMIOLOGICALLY TO THE CURRENT EPIDEMIC OF AIDS. IT SHOULD BE POSSIBLE NOT ONLY TO INTERFERE WITH VIRAL PROPOGATION IN A CHEMOTHERAPEUTIC MANNER BUT ALSO TO EFFECT IMMUNOPROPHYLAXIS IN THE AT-RISK POPULATION, AS THE SYNDROME HAS AN INFECTIOUS ETIOLOGY. THEAIM OF THIS PROJECT IS TO IDENTIFY VIRALLY ENCODED ANTIGENICDETERMINANTS THAT ARE PRODUCED IN A RECOMBINANT DNA EXPRESSION VECTOR BY IMMUNOSCREENING PROTOCOLS. WELL- CHARACTERIZED RECOMBINANT HTLV-III ANTIGENS MAY SERVE AS SEROTYPIC MARKERS OF DISEASE AND WILL BE ASSAYED FOR THEIR EFFECT IN BLOCKING IN VITRO MEASURES OF NEUTRALIZATION. A RECOMBINANT EPITOPE EFFECTIVE IN THE LATTER ASSAY WOULD BE APRIME CANDIDATE FOR A RECOMBINANT SUBUNIT VACCINE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government